US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Turn Therapeutics (Direct Listing)

3.40

-0.0950-2.72%

Volume:325.00

Turnover:1.12K

Market Cap:99.97M

PE:-26.33

High:3.49

Open:3.49

Low:3.40

Close:3.49

52wk High:26.50

52wk Low:2.57

Shares:29.45M

Float Shares:17.87M

Volume Ratio:0.46

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1289

EPS(LYR):-0.0659

ROE:-2324.83%

ROA:-78.67%

PB:198.34

PE(LYR):-51.54

Loading ...

Overview Company News Filings

Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor

Turn Therapeutics Unveils Novel Topical Immunomodulation Approach Targeting Eczema and Inflammatory Diseases

Turn Therapeutics to Present Dermatology Pipeline Update at Major Healthcare Conferences

Turn Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Martin William Dewhurst

Turn Therapeutics Advances GX-03 Eczema Trial, Opening a New Catalyst for Investors

BRIEF-Turn Therapeutics Announces Corporate And Pipeline Updates And 2026 Outlook Ahead Of The 44Th Annual J.P. Morgan Healthcare Conference

Turn Therapeutics Appoints Martin Dewhurst to Board of Directors

Turn Therapeutics Appoints Martin Dewhurst to Board of Directors

Turn Therapeutics Unveils Immunomodulation Platform Targeting Eczema and Inflammatory Diseases

Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares

Director Arthur F. Golden Reports Acquisition of Turn Therapeutics Inc. Common Shares

Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares

Interim CFO Zuraiz Chaudhary Acquires Common Shares of Turn Therapeutics Inc

Turn Therapeutics Reports Third Quarter Net Loss of $1.9 Million

Turn Therapeutics Qtrly EPS $-0.07

THOMSON REUTERS

Turn Therapeutics' GX-03 Named Top Innovation in Atopic Dermatitis Treatment

Turn Therapeutics CEO Discusses Restoring Public Trust in Science with Former CDC Director

Turn Therapeutics Names Andrew Scott Vice President of Corporate Communications

Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications

THOMSON REUTERS

Turn Therapeutics Enters Global Supply, Development, and License Agreement With Leading Medical-Surgical Product Manufacturer and Distributor Medline

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TTRX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TTRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTRX\",,,,,undefined,":{"symbol":"TTRX","market":"US","secType":"STK","nameCN":"Turn Therapeutics (Direct Listing)","latestPrice":3.395,"timestamp":1771858146151,"preClose":3.49,"halted":0,"volume":325,"delay":0,"changeRate":-0.02722063037249289,"floatShares":17868800,"shares":29445200,"eps":-0.12892704,"marketStatus":"Trading","change":-0.095,"latestTime":"02-23 09:52:31 EST","open":3.49,"high":3.49,"low":3.395,"amount":1123.84025,"amplitude":0.027221,"askPrice":3.48,"askSize":100,"bidPrice":3.2,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.12892704,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":2,"adr":0,"listingDate":1759896000000,"exchange":"NASDAQ","adjPreClose":3.49,"postHourTrading":{"tag":"盘后","latestPrice":3.49,"preClose":3.49,"latestTime":"16:45 EST","volume":24,"amount":83.76,"timestamp":1771623901914,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.46236},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTRX\",,,,,undefined,":{"symbol":"TTRX","floatShares":17868800,"roa":"-78.67%","roe":"-2324.83%","lyrEps":-0.065873,"volumeRatio":0.46236,"shares":29445200,"dividePrice":0,"high":3.49,"amplitude":0.027221,"preClose":3.49,"low":3.395,"week52Low":2.5701,"pbRate":"198.34","week52High":26.5,"institutionHeld":0,"latestPrice":3.395,"eps":-0.12892704,"divideRate":0,"volume":325,"delay":0,"ttmEps":-0.12892704,"open":3.49,"prevYearClose":3.94,"prevWeekClose":3.49,"prevMonthClose":4.12,"prevQuarterClose":3.94,"fiveDayClose":3.51,"twentyDayClose":4.86,"sixtyDayClose":3.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TTRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TTRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TTRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1768971600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TTRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TTRX","date":"2026-02-20","current":-27.069574,"percent":0.758242,"low":-100.764104,"twenty":-48.027239,"median":-33.584888,"eighty":-25.643857,"high":-21.019642,"avg":-37.514037,"sd":14.813021,"marketCap":100113622},"quantilePoints":[{"date":"2025-10-10","current":-100.764104,"twenty":-95.944951,"median":-88.716222,"eighty":-81.487493,"marketCap":257809999},{"date":"2025-10-17","current":-61.772777,"twenty":-80.611283,"median":-71.301556,"eighty":-62.49565,"marketCap":158048738},{"date":"2025-10-24","current":-54.215469,"twenty":-75.594983,"median":-58.815569,"eighty":-54.127848,"marketCap":138712988},{"date":"2025-10-31","current":-57.391729,"twenty":-70.118673,"median":-57.391729,"eighty":-54.25928,"marketCap":146839608},{"date":"2025-11-07","current":-46.548635,"twenty":-64.664269,"median":-55.529784,"eighty":-49.111548,"marketCap":119097010},{"date":"2025-11-14","current":-44.796216,"twenty":-60.918473,"median":-54.215469,"eighty":-46.701972,"marketCap":114613358},{"date":"2025-11-21","current":-21.019642,"twenty":-57.501255,"median":-52.517813,"eighty":-44.182869,"marketCap":79796445},{"date":"2025-11-28","current":-27.302265,"twenty":-57.501255,"median":-48.301054,"eighty":-27.302265,"marketCap":103647044},{"date":"2025-12-05","current":-32.964383,"twenty":-57.391729,"median":-47.315318,"eighty":-27.302265,"marketCap":125142027},{"date":"2025-12-12","current":-24.897804,"twenty":-55.858362,"median":-45.508136,"eighty":-26.138816,"marketCap":94519037},{"date":"2025-12-19","current":-23.268976,"twenty":-55.63931,"median":-44.029532,"eighty":-25.595874,"marketCap":88335549},{"date":"2025-12-26","current":-23.036286,"twenty":-55.464068,"median":-42.496165,"eighty":-24.137684,"marketCap":87452193},{"date":"2026-01-02","current":-30.559922,"twenty":-54.828816,"median":-32.964383,"eighty":-24.075634,"marketCap":116014021},{"date":"2026-01-09","current":-36.066913,"twenty":-54.30309,"median":-35.136154,"eighty":-24.292811,"marketCap":136920100},{"date":"2026-01-16","current":-37.385488,"twenty":-54.149753,"median":-35.834223,"eighty":-24.680627,"marketCap":141925782},{"date":"2026-01-23","current":-36.687419,"twenty":-53.711649,"median":-35.834223,"eighty":-25.083956,"marketCap":139275715},{"date":"2026-01-30","current":-33.740015,"twenty":-52.638292,"median":-35.911787,"eighty":-25.45626,"marketCap":128086546},{"date":"2026-02-06","current":-28.698404,"twenty":-50.513483,"median":-35.446407,"eighty":-25.69184,"marketCap":108947177},{"date":"2026-02-13","current":-27.806427,"twenty":-48.322959,"median":-35.097373,"eighty":-25.925975,"marketCap":105560981},{"date":"2026-02-20","current":-26.371506,"twenty":-48.027239,"median":-33.584888,"eighty":-25.643857,"marketCap":100113622}],"updateTime":1771816067420},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TTRX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612529554","title":"Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2612529554","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612529554?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:02","pubTimestamp":1771333361,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. has appointed Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs. Dr. Redfield will provide strategic guidance on the clinical development and public health aspects of the company's lead investigational therapy, GX-03, which is in Phase 2 clinical trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDLbrsfPQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"gpt_icon":0},{"id":"2610658022","title":"Turn Therapeutics Unveils Novel Topical Immunomodulation Approach Targeting Eczema and Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2610658022","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610658022?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:05","pubTimestamp":1770642355,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. has released a corporate presentation outlining its development of first-in-class, precision, non-systemic immunomodulation therapies targeting IL-36 and key downstream cytokines for inflammatory diseases, with an initial focus on moderate to severe eczema. The company’s lead candidate, GX-03, is a topical IL-36/IL-31/IL-4 inhibitor currently in a Phase 2 randomized controlled trial for moderate to severe eczema, with topline results expected in mid-2026. GX-03’s active pharmaceutical ingredient is classified as a New Chemical Entity in the United States and is supported by strong patent coverage through 2037. More than 200,000 applications of GX-03 have been reported with no adverse events. Additional indications in the pipeline include onychomycosis and psoriasis. Turn Therapeutics also highlights its PermaFusion delivery platform, which enables stable, emulsifier-free dispersion of active ingredients. Phase 1-level safety data from a 53-patient study reported ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL4gmxtR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"gpt_icon":0},{"id":"2610465840","title":"Turn Therapeutics to Present Dermatology Pipeline Update at Major Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2610465840","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610465840?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:01","pubTimestamp":1770642083,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDLb2Mgtx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"gpt_icon":0},{"id":"2608369286","title":"Turn Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Martin William Dewhurst","url":"https://stock-news.laohu8.com/highlight/detail?id=2608369286","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608369286?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:30","pubTimestamp":1770208255,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing identifies Martin William Dewhurst as a director and the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL1FYlZ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Turn Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Martin William Dewhurst","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"gpt_icon":0},{"id":"2605481867","title":"Turn Therapeutics Advances GX-03 Eczema Trial, Opening a New Catalyst for Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2605481867","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605481867?lang=en_us&edition=fundamental","pubTime":"2026-01-22 00:37","pubTimestamp":1769013478,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc ($TTRX) announced an update on their ongoing clinical study. Turn Therapeutics Inc. (TTRX) has launched a Phase 2 clinical tr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-advances-gx-03-eczema-trial-opening-a-new-catalyst-for-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-advances-gx-03-eczema-trial-opening-a-new-catalyst-for-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","TTRX","BK4007","ISBC","BK4211"],"gpt_icon":0},{"id":"2602548514","title":"BRIEF-Turn Therapeutics Announces Corporate And Pipeline Updates And 2026 Outlook Ahead Of The 44Th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548514","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548514?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:26","pubTimestamp":1768224392,"startTime":"0","endTime":"0","summary":"BRIEF-Turn Therapeutics Announces Corporate And Pipeline Updates And 2026 Outlook Ahead Of The 44Th Annual J.P. Morgan Healthcare ConferenceJan 12 (Reuters) - Turn Therapeutics Inc TTRX.O:TURN THERAPE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA3WYB7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"gpt_icon":0},{"id":"2602510999","title":"Turn Therapeutics Appoints Martin Dewhurst to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510999","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510999?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:05","pubTimestamp":1768223136,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. has appointed Martin Dewhurst, a veteran with over 30 years of experience at McKinsey & Company in M&A, to its board of directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL2mJMYF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"gpt_icon":0},{"id":"2601389581","title":"Turn Therapeutics Appoints Martin Dewhurst to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389581","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389581?lang=en_us&edition=fundamental","pubTime":"2026-01-08 05:05","pubTimestamp":1767819924,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. has appointed Martin Dewhurst to its Board of Directors. Dewhurst brings over 30 years of global life sciences and M&A experience, including leadership roles at McKinsey & Company and co-founding the McKinsey Health Institute. He also serves as a senior advisor to PJT Partners and holds board positions in other healthcare organizations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL6TZYk1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","TTRX","LU2210150020.SGD","NDAQ","BK4127","SG9999014039.USD","LU2210149790.SGD","PJT","LU2095319765.USD","BK4112","BK4007","BK4585","BK4588","SG9999014021.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2601380069","title":"Turn Therapeutics Unveils Immunomodulation Platform Targeting Eczema and Inflammatory Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2601380069","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601380069?lang=en_us&edition=fundamental","pubTime":"2026-01-08 01:19","pubTimestamp":1767806396,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. has released a corporate presentation detailing its pipeline and development strategy for inflammatory disease treatments. The company is advancing GX-03, a non-systemic, topical immunomodulator targeting IL-36 and related cytokines, with a primary focus on moderate to severe eczema. The Phase 2 trial for GX-03 is underway, with an interim analysis expected in the first quarter of 2026 and topline data anticipated in the second quarter of 2026. Phase 3 studies are expected to begin in the second half of 2026. Additional pipeline candidates include treatments for onychomycosis and psoriasis, as well as thermostable vaccine platforms. The company’s PermaFusion technology underpins its proprietary drug delivery approach. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated co","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL68h6zc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"gpt_icon":0},{"id":"2591682942","title":"Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591682942","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591682942?lang=en_us&edition=fundamental","pubTime":"2025-12-13 07:00","pubTimestamp":1765580441,"startTime":"0","endTime":"0","summary":"Zuraiz Chaudhary, an officer of Turn Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 12, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL86Sw0z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"gpt_icon":0},{"id":"2586496163","title":"Director Arthur F. Golden Reports Acquisition of Turn Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586496163","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586496163?lang=en_us&edition=fundamental","pubTime":"2025-11-25 00:20","pubTimestamp":1764001222,"startTime":"0","endTime":"0","summary":"Arthur F. Golden, a director of Turn Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL5jBsHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Arthur F. Golden Reports Acquisition of Turn Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"gpt_icon":0},{"id":"2585998121","title":"Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585998121","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585998121?lang=en_us&edition=fundamental","pubTime":"2025-11-22 06:44","pubTimestamp":1763765067,"startTime":"0","endTime":"0","summary":"Zuraiz Chaudhary, an officer of Turn Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL6Sg0qK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"gpt_icon":0},{"id":"2584043636","title":"Interim CFO Zuraiz Chaudhary Acquires Common Shares of Turn Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2584043636","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584043636?lang=en_us&edition=fundamental","pubTime":"2025-11-18 10:24","pubTimestamp":1763432651,"startTime":"0","endTime":"0","summary":"Zuraiz Chaudhary, Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer, reported the acquisition of common shares of Turn Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL3mbZRJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Interim CFO Zuraiz Chaudhary Acquires Common Shares of Turn Therapeutics Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"gpt_icon":0},{"id":"2583560731","title":"Turn Therapeutics Reports Third Quarter Net Loss of $1.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583560731","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583560731?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:00","pubTimestamp":1763038829,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. reported a net loss of $1.9 million for the three months ended September 30, 2025, compared to a net loss of $0.7 million for the same period in 2024. General and administrative expenses rose to $1.8 million from $0.5 million, mainly due to increased legal and advisory fees associated with the company's direct listing on Nasdaq. As of September 30, 2025, the company had $3.1 million in cash and cash equivalents, up from $0.9 million at the end of 2024. Turn Therapeutics began trading on Nasdaq on October 8, 2025, and expanded its board and executive team during the period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Glob","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL7Jj36W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","TTRX","BK4007","LU2210149790.SGD","BK4585","LU2095319765.USD","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","BK4588","LU0314104364.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2583598646","title":"Turn Therapeutics Qtrly EPS $-0.07","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598646","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598646?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:00","pubTimestamp":1763038807,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA51HKVG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"gpt_icon":0},{"id":"2582375505","title":"Turn Therapeutics' GX-03 Named Top Innovation in Atopic Dermatitis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375505","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375505?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:12","pubTimestamp":1762949555,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. announced that its GX-03 technology, a topical IL36/IL31 inhibitor, has been recognized as one of \"Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment\" by Patient Care Online Magazine. The company highlighted that GX-03 represents the first topical agent targeting IL-36, a key player in the inflammatory processes of atopic dermatitis, eczema, and psoriasis. Preclinical studies showed GX-03's ability to inhibit several targets, including IL-36 alpha, IL-31, IL-4, and IL-36 gamma. Turn Therapeutics stated that topline data from its lead program in severe eczema will be announced in early 2026. Research results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7cVkQw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"gpt_icon":0},{"id":"2582397951","title":"Turn Therapeutics CEO Discusses Restoring Public Trust in Science with Former CDC Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2582397951","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582397951?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:05","pubTimestamp":1762895111,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc.  CEO Bradley Burnam recently held an interview with Dr. Robert Redfield, M.D., former Director of the Centers for Disease Control and Prevention . Their conversation focused on healthcare communication, pandemic preparedness, and restoring public trust in science, with both leaders emphasizing the importance of fact-based reporting in public health. The interview, titled \"Redfield's Warning: Former CDC Director on COVID's Biggest Casualty-Trust in Science,\" is available on all major podcast platforms, YouTube, and the Turn Therapeutics IR Website. The full interview can be accessed at Turn Therapeutics IR Website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL1sNYRc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4007","TTRX","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","BK4588","NDAQ","LU2095319765.USD","IE00BKPKM429.USD","BK4585","LU2210150020.SGD"],"gpt_icon":0},{"id":"2581760449","title":"Turn Therapeutics Names Andrew Scott Vice President of Corporate Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2581760449","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581760449?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:07","pubTimestamp":1762294054,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc. has appointed Andrew Scott as Vice President of Corporate Communications. In this role, Scott will oversee investor relations, capital markets strategy, and corporate communications, as well as support the company's licensing and partnership initiatives. Scott brings over 30 years of experience in capital markets and corporate finance, previously serving at ThinkEquity LLC and Fortress Biosciences, Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL4BDDtB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","LU2095319765.USD","BK4585","BK4588","LU2210149790.SGD","BK4112","TTRX","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2581470760","title":"Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2581470760","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581470760?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:07","pubTimestamp":1762294046,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA30PF7N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX"],"gpt_icon":0},{"id":"2579478148","title":"Turn Therapeutics Enters Global Supply, Development, and License Agreement With Leading Medical-Surgical Product Manufacturer and Distributor Medline","url":"https://stock-news.laohu8.com/highlight/detail?id=2579478148","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579478148?lang=en_us&edition=fundamental","pubTime":"2025-10-30 19:30","pubTimestamp":1761823801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUAB274NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}